Remdesivir has ‘little effect’ on Covid-19 death risks, WHO study says
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard
THURSDAY, MAY 19, 2022
THURSDAY, MAY 19, 2022
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
Remdesivir has ‘little effect’ on Covid-19 death risks, WHO study says

Coronavirus chronicle

Reuters
16 October, 2020, 08:50 am
Last modified: 16 October, 2020, 09:53 am

Related News

  • 22 Covid cases reported in 24hrs
  • China Junshi's potential Covid drug shows promise in small trial
  • Indonesia to drop outdoor mask mandate as Covid-19 infections drop
  • US calls for Taiwan's inclusion at upcoming WHO assembly
  • N Korean leader slams officials' 'immaturity' in response to Covid outbreak

Remdesivir has ‘little effect’ on Covid-19 death risks, WHO study says

The study found the regimens appeared to have little or no effect on 28-day mortality or the length of the in-hospital course among patients hospitalized with Covid-19

Reuters
16 October, 2020, 08:50 am
Last modified: 16 October, 2020, 09:53 am
Gilead Sciences Inc pharmaceutical company is seen after they announced a Phase 3 Trial of the investigational antiviral drug Remdesivir in patients with severe coronavirus disease (Covid-19), during the outbreak of the coronavirus disease (Covid-19), in Oceanside, California, US, April 29, 2020. Photo: Reuters
Gilead Sciences Inc pharmaceutical company is seen after they announced a Phase 3 Trial of the investigational antiviral drug Remdesivir in patients with severe coronavirus disease (Covid-19), during the outbreak of the coronavirus disease (Covid-19), in Oceanside, California, US, April 29, 2020. Photo: Reuters

Gilead Sciences Inc's GILD.O remdesivir had little or no effect on Covid-19 patients' length of hospital stay or chances of survival, a clinical trial by the World Health Organization (WHO) has found.

The antiviral medication, among the first to be used as a treatment for Covid-19, was one of the drugs recently used to treat US President Donald Trump's coronavirus infection.

The results are from WHO's "Solidarity" trial, which evaluated the effects of four potential drug regimens, including remdesivir, hydroxychloroquine, anti-HIV drug combination lopinavir/ritonavir and interferon, in 11,266 adult patients across more than 30 countries.

The study found the regimens appeared to have little or no effect on 28-day mortality or the length of the in-hospital course among patients hospitalized with Covid-19, the WHO said on Thursday.

The results of the trial are yet to be reviewed and were uploaded on the preprint server medRxiv. 

Earlier this month, data from a US study of remdesivir by Gilead showed the treatment cut Covid-19 recovery time by five days compared with patients who got a placebo in a trial comprising 1,062 patients.

"The emerging (WHO) data appears inconsistent, with more robust evidence from multiple randomized, controlled studies published in peer-reviewed journals validating the clinical benefit of remdesivir," Gilead told Reuters.

"We are concerned the data from this open-label global trial has not undergone the rigorous review required to allow for constructive scientific discussion, particularly given the limitations of the trial design."

WHO chief scientist Soumya Swaminathan said on Wednesday that during the study, hydroxychloroquine and lopinavir/ritonavir were stopped in June after they proved ineffective, but other trials continued in more than 500 hospitals and 30 countries.

"We're looking at what's next. We're looking at monoclonal anti-bodies, we're looking at immunomodulators and some of the newer anti-viral drugs that have been developed in the last few months," Swaminathan said.

Remdesivir received emergency use authorization from the US Food and Drug Administration on May 1, and has since been authorized for use in several countries.

Top News / World+Biz

remdesivir / WHO / Covid -19

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Govt’s bank borrowing 43% of target in 10 months of FY22
    Govt’s bank borrowing 43% of target in 10 months of FY22
  • Fiscal consolidation is a way out
    Fiscal consolidation is a way out
  • Finance Minister AHM Mustafa Kamal, Photo: TBS
    Annual foreign debts can be paid with two months’ remittance: Finance minister

MOST VIEWED

  • Medical staff members check the temperature of people as they enter at Capital Airport, following an outbreak of Covid-19, in Beijing, China, 5 November, 2020. Photo: Reuters
    China relaxes some Covid test rules for US, other travellers
  • Representational image.
    China Junshi's potential Covid drug shows promise in small trial
  • A woman wearing protective mask walks at a sidewalk near business district in Jakarta, Indonesia March 2, 2020. REUTERS/Willy Kurniawan/Files
    Indonesia to drop outdoor mask mandate as Covid-19 infections drop
  • North Korean leader Kim Jong Un presides over a politburo meeting of the ruling Workers' Party, amid the coronavirus disease (COVID-19) pandemic, May 17, 2022, in this photo released May 18, 2022 by North Korea's Korean Central News Agency (KCNA). KCNA via REUTERS
    N Korean leader slams officials' 'immaturity' in response to Covid outbreak
  • North Korea Covid outbreak is 'worrying' for new variants -WHO
    North Korea Covid outbreak is 'worrying' for new variants -WHO
  • People watch a TV broadcasting a news report on the coronavirus disease (Covid-19) outbreak in North Korea, at a railway station in Seoul, South Korea on 17 May 2022. Photo: Reuters.
    N Korea Covid outbreak could have 'devastating' impact on human rights, UN says

Related News

  • 22 Covid cases reported in 24hrs
  • China Junshi's potential Covid drug shows promise in small trial
  • Indonesia to drop outdoor mask mandate as Covid-19 infections drop
  • US calls for Taiwan's inclusion at upcoming WHO assembly
  • N Korean leader slams officials' 'immaturity' in response to Covid outbreak

Features

Sketch: TBS

'Food inflation is an unavoidable consequence of currency devaluation'

11h | Interviews
The open-browser-tabs question also tells an interviewer how much of an internet native the job applicant might be. Photo: Noor-a-Alam

The best question to ask a job applicant

11h | Pursuit
Illustration: TBS

Ugly business: Politics in workplace

10h | Pursuit
Illustration: TBS

‘Do you have insurance?’: Life of a life insurance agent

13h | Panorama

More Videos from TBS

Putin's strategies to face Nato

Putin's strategies to face Nato

34m | Videos
How many countries have nuclear weapons and how many are there?

How many countries have nuclear weapons and how many are there?

49m | Videos
Dengue fever is rising, so beware

Dengue fever is rising, so beware

59m | Videos
How a university teacher and PHD holder become farmer

How a university teacher and PHD holder become farmer

5h | Videos

Most Read

1
Tk100 for bike, Tk2,400 for bus to cross Padma Bridge
Bangladesh

Tk100 for bike, Tk2,400 for bus to cross Padma Bridge

2
Representative Photo: Pixabay.
Bangladesh

Microplastics found in 5 local sugar brands

3
Mushfiq Mobarak. Photo: Noor-A-Alam
Panorama

Meet the Yale professor who anchors his research in Bangladesh and scales up interventions globally

4
A packet of US five-dollar bills is inspected at the Bureau of Engraving and Printing in Washington March 26, 2015. REUTERS/Gary Cameron
Banking

Dollar hits Tk100 mark in open market

5
The story of Bangladesh becoming a major bicycle exporter
Industry

The story of Bangladesh becoming a major bicycle exporter

6
PK Halder: How a scamster rose from humble beginnings to a Tk11,000cr empire
Crime

PK Halder: How a scamster rose from humble beginnings to a Tk11,000cr empire

The Business Standard
Top
  • Home
  • Entertainment
  • Sports
  • About Us
  • Bangladesh
  • International
  • Privacy Policy
  • Comment Policy
  • Contact Us
  • Economy
  • Sitemap
  • RSS

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net

Copyright © 2022 THE BUSINESS STANDARD All rights reserved. Technical Partner: RSI Lab